Keryx Biopharmaceuticals Inc.
750 Lexington Avenue
20th Floor
New York,
NY 10022
United States - Map
Phone: 212-531-5965
Fax: 212-531-5961
Web Site: http://www.keryx.com
| Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was formerly known as Lakaro Biopharmaceuticals, Inc. and changed its name to Keryx Biopharmaceuticals, Inc. in January 2000. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. James F. Oliviero , 34
Principal Financial Officer, Principal Accounting Officer, Sec. and Treasurer |
$
265.00K | N/A | Mr. Ron Bentsur , 44
Chief Exec. Officer |
N/A
| N/A | Mr. Michael Chiang ,
Exec. Pres |
N/A
| N/A | Mr. William P. Kane ,
VP of Commercial Operations |
N/A
| N/A | Mr. Lou DeBergalis ,
Pres of Quality Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
